GLUREDIA

A longitudinal study of the glucagon response to low blood sugar (hypoglycemia) in newly diagnosed children and adolescents with type 1 diabetes: characteristics and predictive biomarkers

The GLUREDIA study aims to better understand how the body protects itself against low blood sugar (hypoglycemia) in children and adolescents aged 2 to 18 years with type 1 diabetes. In particular, researchers are investigating the function of pancreatic alpha cells and the hormones involved in restoring blood sugar levels when they become too low.

By studying these mechanisms alongside individual characteristics of diabetes and potential genetic factors, GLUREDIA seeks to identify patients who may be at greater risk of severe hypoglycemia. The findings could ultimately contribute to more personalised approaches to the monitoring and management of type 1 diabetes in children and adolescents.

Want to know more?

For further information, please contact the study team.

About the study

Recruiting
Patients 2–18 years
Pediatrics & Rare diseases

Locations

Centre Hospitalier de Luxembourg – CHL KannerKlinik CHL KannerKlinik
4, rue Ernest Barblé
L-1210 Luxembourg

Contact

Prof. Dr Marianne Becker

Eligible participants

  • Children between 2 and 18 years of age.
  • Have been newly diagnosed with type 1 diabetes.
  • Meet the study’s diagnostic criteria for type 1 diabetes, including elevated blood glucose and/or HbA1c levels and the presence of one or more diabetes-related autoantibodies.
  • Body weight of at least 17 kg, as required for the study blood collections.
  • Informed consent signed by the parents or legal representative if applicable.

Exclusion criteria

  • Children not meeting the age requirement.
  • Use of certain medications that may interfere with insulin secretion or insulin sensitivity.
  • Diagnosis of another autoimmune or autoinflammatory disease, or an active cancer at the time of inclusion.
  • Presence of severe obesity, as defined by the study protocol.
  • Presence of liver, kidney, or adrenal insufficiency.
  • Previous bone marrow transplant.
  • History of diabetes following a haemolytic uraemic syndrome.
  • Epilepsy.
  • Dysmorphia with suspicion of an underlying genetic syndrome.

Study procedures?

01.

Clinical and blood sugar data

collected during child’s routine diabetes consultations will be used throughout the study.

02.

Completion of a questionnaire about hypoglycemia,

including any previous episodes of severe hypoglycemia and how they were managed. This will help researchers to assess the individual risk of hypoglycemia.

03.

Blood samples will be collected to measure glucagon and other hormones

involved in the body’s response to low blood sugar. Whenever possible, these samples will be coordinated with routine diabetes visits and blood tests to avoid additional appointments and venous punctions.

04.

The child may undergo a specific test of glucagon secretion (optional).

This involves arriving fasting, having a small intravenous catheter inserted, receiving their usual insulin dose and for a defined meal or nutritional drink, and providing three blood samples at approximately 1.5-hour intervals.

05.

Optional genetic analysis

may also be performed (with specific consent). This will focus on genes related to type 1 diabetes and the body’s mechanisms for regulating blood sugar.

Contact & location

Centre Hospitalier de Luxembourg – CHL KannerKlinik

Centre Hospitalier de Luxembourg – CHL KannerKlinik

CHL KannerKlinik
4, rue Ernest Barblé
L-1210 Luxembourg

Principal Investigator

Prof. Dr Marianne Becker

Prof. Dr Marianne Becker

Endocrinologie-Diabétologie Pédiatrique

Centre Hospitalier de Luxembourg (CHL)
Prof. Philippe Lysy

Prof. Philippe Lysy

Department of Specialised Pediatrics

Cliniques universitaires Saint-Luc (CUSL) (Belgium)

Participating institutions

The GLUREDIA study is sponsored by the Cliniques universitaires St-Luc, Bruxelles, Belgium and involves multiple clinical sites across Belgium; the Centre Hospitalier de Luxembourg is the only clinical site outside Belgium.

Funded by

Cliniques universitaires St-Luc, Bruxelles, Belgium, with the support of CHL

Related news & updates

Related events

29 Sep – 1 Oct 2026

Clinical Research Luxembourg Conference

08:00 – 17:00
Luxexpo The Box

Why does clinical research matter today in Luxembourg? Clinical research plays a vital role in improving patient care, driving medical…

Luxembourg Research Clinic
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.